Abstract PS11-11: Targeted Safety Events from a Phase I/Ib Study Evaluating GDC-0077 Alone and in Combination with Endocrine Therapy (ET) ± Palbociclib (palbo) in Patients (pts) with PIK3CA-mutant (mut), Hormone Receptor-Positive/her2-negative Metastatic Breast Cancer (HR+/HER2- Mbc)
Cancer Research（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要